Global Human Parenteral Nutrition Market Growth (Status and Outlook) 2023-2029

Global Human Parenteral Nutrition Market Growth (Status and Outlook) 2023-2029

Parenteral nutrition is the medical term for infusing a specialized form of food through a vein (intravenously). The goal of the treatment is to cure or prevent malnutrition. Human Parenteral nutrition provides liquid nutrients, including carbohydrates, proteins, fats, vitamins, minerals, and electrolytes. Some people use parenteral nutrition to feed various vitamin or protein supplements through a tube placed into the stomach or small bowel.

LPI (LP Information)' newest research report, the “Human Parenteral Nutrition Industry Forecast” looks at past sales and reviews total world Human Parenteral Nutrition sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Parenteral Nutrition sales for 2023 through 2029. With Human Parenteral Nutrition sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Parenteral Nutrition industry.

This Insight Report provides a comprehensive analysis of the global Human Parenteral Nutrition landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Parenteral Nutrition portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Parenteral Nutrition market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Parenteral Nutrition and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Parenteral Nutrition.

The global Human Parenteral Nutrition market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Human Parenteral Nutrition is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Human Parenteral Nutrition is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Human Parenteral Nutrition is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Human Parenteral Nutrition players cover Baxter, Allergan, Actavis Inc., Otsuka Pharmaceutical Factory, Inc., Grifols, S.A., B. Braun Melsungen AG, Vifor Pharma, Fresenius Kabi AG and Sichuan Kelun Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Parenteral Nutrition market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Carbohydrate Nutrition
Parenteral Lipid Emulsion Nutrition
Single Dose Amino Acid Solution Nutrition
Trace Element Nutrition
Vitamins & Mineral Nutrition

Segmentation by application
Hospital
Clinic
Nursing Home

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxter
Allergan
Actavis Inc.
Otsuka Pharmaceutical Factory, Inc.
Grifols, S.A.
B. Braun Melsungen AG
Vifor Pharma
Fresenius Kabi AG
Sichuan Kelun Pharmaceutical Co., Ltd.
Pfizer Inc. (Hospira Inc.)

Please note: The report will take approximately 2 business days to prepare and deliver.